Article
Nocturia: An update on diagnosis and treatment
Author(s):
In this video, Alan J. Wein, MD, PhD, discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; and the role of a voiding diary in patient care.
Nocturia has been poorly managed in the past, but renewed interest in its pathophysiology and management has led to improved understanding of this common condition, according to Alan J. Wein, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
In this Urology Times interview, Dr. Wein discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; the role of a voiding diary in patient care; and “quick hits” that he recommends clinicians address first in patients with nocturia.
Dr. Wein is a consultant/adviser or meeting participant for Allergan, Medtronic, Axonics, Outpost, Velicept, Serenity, Aquinox, Avadel, Valencia, and Urovant.
